Cholesterol synthesis pathway genes in prostate cancer are transcriptionally downregulated when tissue confounding is minimized

• Published in: BMC cancer Vol. 18; no. 1; p. 478
• Main Authors: Rye, Morten Beck, Bertilsson, Helena, Andersen, Maria K, Rise, Kjersti, Bathen, Tone F, Drabløs, Finn, Tessem, May-Britt
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 27-04-2018; BioMed Central; BMC
• Subjects: Analysis; Biosynthetic Pathways - genetics; Cholesterol; Cholesterol - biosynthesis; Cohort Studies; Development and progression; Down-Regulation; Gene expression; Gene expression analysis; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Genetic aspects; Health aspects; HMGCR; Humans; Lipid Metabolism - genetics; Male; Models, Biological; Prostate cancer; Prostatic Neoplasms - genetics; Prostatic Neoplasms - metabolism; Prostatic Neoplasms - pathology; Reproducibility of Results; RNA sequencing; Stroma; Stromal Cells - metabolism; Stromal Cells - pathology; Tissue engineering; Tissue heterogeneity; Transcription, Genetic; Gene expression analysis; RNA-Seq; Stroma; GSEA; HMGCR; Tissue heterogeneity; Prostate cancer; Cholesterol
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/s12885-018-4373-y

The relationship between cholesterol and prostate cancer has been extensively studied for decades, where high levels of cellular cholesterol are generally associated with cancer progression and less favorable outcomes. However, the role of in vivo cellular cholesterol synthesis in this process is unclear, and data on the transcriptional activity of cholesterol synthesis pathway genes in tissue from prostate cancer patients are inconsistent.
A common problem with cancer tissue data from patient cohorts is the presence of heterogeneous tissue which confounds molecular analysis of the samples. In this study we present a general method to minimize systematic confounding from stroma tissue in any prostate cancer cohort comparing prostate cancer and normal samples. In particular we use samples assessed by histopathology to identify genes enriched and depleted in prostate stroma. These genes are then used to assess stroma content in tissue samples from other prostate cancer cohorts where no histopathology is available. Differential expression analysis is performed by comparing cancer and normal samples where the average stroma content has been balanced between the sample groups. In total we analyzed seven patient cohorts with prostate cancer consisting of 1713 prostate cancer and 230 normal tissue samples.
When stroma confounding was minimized, differential gene expression analysis over all cohorts showed robust and consistent downregulation of nearly all genes in the cholesterol synthesis pathway. Additional Gene Ontology analysis also identified cholesterol synthesis as the most significantly altered metabolic pathway in prostate cancer at the transcriptional level.
The surprising observation that cholesterol synthesis genes are downregulated in prostate cancer is important for our understanding of how prostate cancer cells regulate cholesterol levels in vivo. Moreover, we show that tissue heterogeneity explains the lack of consistency in previous expression analysis of cholesterol synthesis genes in prostate cancer.